Dozens of Healthcare and Biotech Companies Showcase Pipelines and Launch Plans at Morgan Stanley, Jefferies and H.C. Wainwright Conferences

September 14, 2026 saw a broad wave of healthcare and biotech presentations across three major investor conferences, with the Morgan Stanley 24th Annual Global Healthcare Conference drawing the largest roster of companies. Presenters ranged from large-cap names such as Johnson and Johnson, Eli Lilly, Takeda and Royalty Pharma to clinical-stage biotechs, each outlining near-term commercial or regulatory milestones.

Eli Lilly used the Morgan Stanley stage to reinforce its obesity franchise, while Takeda signaled a shift from pipeline building toward product launches. Viking Therapeutics and United Therapeutics also addressed obesity and fibrosis programs respectively, and Insmed, Denali Therapeutics and CG Oncology pointed to building launch momentum for their lead assets. Royalty Pharma framed its growth story as extending beyond traditional royalty streams.

At the H.C. Wainwright conference, Solid Biosciences flagged upcoming FDA milestones, SpyGlass Pharma advanced its glaucoma program, and Artiva Biotherapeutics outlined a Phase 3 push. Zentalis highlighted its azenosertib program at Morgan Stanley, while Zevra described a larger-than-expected rare-disease opportunity and Zenas BioPharma emphasized its cash position alongside the obexelimab asset.

Aside from the conference circuit, INmune Bio announced two board appointments, adding a Sanofi rare-disease executive and a biopharma business development leader to strengthen commercialization and partnering capabilities as its Ebstrocel therapy advances. Separately, Radiopharm Theranostics disclosed that its RAD101 PET imaging agent achieved 93% concordance with MRI across all evaluable lesions in a US Phase 2b trial, meeting the primary endpoint, with a brain metastases imaging market estimated at roughly 600 million dollars in total addressable opportunity and an FDA meeting scheduled for October 1 to align on a Phase 3 pivotal trial protocol.